Suppr超能文献

舒芬太尼在危重症儿科患者长期输注期间的药代动力学

Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients.

作者信息

Bartkowska-Śniatkowska Alicja, Bienert Agnieszka, Wiczling Paweł, Rosada-Kurasińska Jowita, Zielińska Marzena, Warzybok Justyna, Borsuk Agnieszka, Tibboel Dick, Kaliszan Roman, Grześkowiak Edmund

机构信息

Department of Pediatric Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences, Poznan, Poland.

Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, Poznan, Poland.

出版信息

J Clin Pharmacol. 2016 Jan;56(1):109-15. doi: 10.1002/jcph.577. Epub 2015 Aug 28.

Abstract

The aim of this study was to develop a population pharmacokinetic model of sufentanil and to assess the influence of covariates in critically ill children admitted to a pediatric intensive care unit. After institutional approval, 41 children were enrolled in the study. Blood samples for pharmacokinetic (PK) assessment were collected from routinely placed arterial catheters during and after discontinuation of infusion. Population nonlinear mixed-effects modeling was performed using NONMEM. A 2-compartment model described sufentanil PK sufficiently. Typical values of the central and peripheral volume of distribution and the metabolic and intercompartmental clearance for a theoretical patient weighing 70 kg were VC = 7.90 l, VT  = 481 L, Cl =  5.3 L/h, and Q = 38.3 L/h, respectively. High interindividual variability of all PK parameters was noted. Allometric/isometric principles to scale sufentanil PK revealed that to achieve the same steady-state sufentanil concentrations in plasma for pediatric patients of different body weights, the infusion rate should follow the formula (infusion rate for a 70-kg adult patient, μg/h) × (body weight/70 kg)(0.75). Severity of illness described by PRISM score, the monitored physiological and laboratory parameters, and coadministered drugs such as vasopressors were not found to be significant covariates.

摘要

本研究的目的是建立舒芬太尼的群体药代动力学模型,并评估协变量对入住儿科重症监护病房的危重症患儿的影响。经机构批准后,41名儿童纳入本研究。在输注期间及停止输注后,从常规放置的动脉导管采集血样用于药代动力学(PK)评估。使用NONMEM进行群体非线性混合效应建模。一个二室模型足以描述舒芬太尼的药代动力学。对于一名体重70 kg的理论患者,中央室和外周室分布容积以及代谢和室间清除率的典型值分别为VC = 7.90 l、VT = 481 L、Cl = 5.3 L/h和Q = 38.3 L/h。注意到所有药代动力学参数存在较大的个体间变异性。根据异速生长/等比生长原理对舒芬太尼药代动力学进行标化后发现,为使不同体重的儿科患者血浆中舒芬太尼达到相同的稳态浓度,输注速率应遵循公式(70 kg成年患者的输注速率,μg/h)×(体重/70 kg)(0.75)。未发现PRISM评分所描述的疾病严重程度、监测的生理和实验室参数以及同时使用的血管加压药等药物是显著的协变量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验